Houdini Bio is a biotechnology research startup developing an AI-powered platform that rewrites therapeutic DNA to evade innate silencing pathways without altering its intended biological function. The platform is applicable across gene therapies, cell therapies and biomanufacturing, and is designed to improve potency inside cells, enabling enhanced durability, lower doses and improved cost effectiveness.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| £1.5 M | Jun, 2026 | unspecified |
Industries
Frequently Asked Questions
Where is Houdini Bio located?
Houdini Bio is located in London, UK.
What industries does Houdini Bio operate in?
Houdini Bio operates in the following industries: Biotechnology Research.
How much total funding has Houdini Bio raised?
Houdini Bio has raised a total of $1,500,000.
Who are the investors in Houdini Bio?
The investors in Houdini Bio are: Science Creates, Deep Science Ventures, Cambridge Enterprise Ventures.
What is the primary mission of Houdini Bio?
The mission of Houdini Bio is to ensure that life-changing genetic medicines are viable, durable, safe, and accessible to everyone by redesigning therapeutic DNA to escape cellular silencing mechanisms.
How does Houdini Bio improve the effectiveness of gene therapies?
Houdini Bio uses machine learning and synthetic biology to identify and bypass the cellular defense systems, such as the HUSH complex, that otherwise recognize and shut down therapeutic DNA as if it were a foreign invader.
Is Houdini Bio the same company that developed the 3D animation software Houdini?
No, Houdini Bio is a biotechnology company focused on genetic medicine, whereas the 3D animation software called Houdini was developed by SideFX, a company based in Toronto.
Who are the founders of Houdini Bio?
Houdini Bio was co-founded by Jonathan Cohen-Gold, who serves as the CEO, and Lee Dunham, who serves as the Chief Business Officer.